Myriad Genetics Inc (MYGN):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Myriad Genetics Inc (MYGN) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7428
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:68
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that analyze genes, their expression levels and corresponding proteins to assess a person risk for developing disease later in life, accurately diagnose disease and determine a patient’s likelihood of responding to a particular drug. It also provides an array of pharmaceutical and clinical services. Myriad markets its products through its sales force in Europe and Canada and through distributor agreements in Latin American, Middle Eastern, Asian and African countries. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, the Netherlands and Italy. Myriad is headquartered in Salt Lake City, Utah, the US.

Myriad Genetics Inc (MYGN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Myriad Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Myriad Genetics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Myriad Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Myriad Genetics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Myriad Genetics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Myriad Genetics Inc, Medical Equipment, Deal Details 13
Venture Financing 13
Myriad Genetics to Raise Funds through Venture Financing 13
AssureRx Health Raises Additional USD15 Million in Series D Financing 14
AssureRx Health Raises USD7 Million in Venture Financing 15
Counsyl Raises US$28 Million In Series D Financing 17
RainDance Technologies Raises US$20 Million In Series E Financing 18
Crescendo Bioscience Raises US$28 Million In Series D Financing 20
Counsyl Secures USD7.5 Million in Series C Funding 22
Assurex Health Secures USD12.5 Million in Series C Funding Round 23
Counsyl Secures USD34 Million in Series B Round of Funding 24
Assurex Health Secures USD8 Million in Venture Funding Round 25
Private Equity 26
Perceptive Advisors Invests USD80 Million in Counsyl 26
Partnerships 27
Myriad Genetics Enters into Licensing Agreement with Institut Curie and INSERM 27
Myriad Genetics Enters into Licensing Agreement With Children’s Medical Center 28
Myriad Genetics Enters into Licensing Agreement with University of Texas 29
Myriad Genetics Enters Into Licensing Agreement For RAD51C Gene 30
Myriad Genetics and Pfizer Enter into Agreement 31
Sividon Diagnostics Enters into Co-Marketing Agreement with Virchow Labs and Ready Ruixin 32
Myriad Genetics Expands Agreement with AstraZeneca 33
Myriad Genetics Enters Into Co-Marketing Agreement With Sividon Diagnostics For EndoPredict Test 34
Myriad Enters Into Research Agreement With Janssen Research & Development 35
Myriad Genetics Expands Agreement with AstraZeneca for Olaparib 36
DaVita Enters Into Agreement With Myriad Genetics For Protein Biomarker Discovery 37
Mount Sinai Genetic Testing Lab And Counsyl Partner To Expand Screening For Genetic Diseases 38
Bio-Rad Labs Enters Into Distribution Agreement With Myriad RBM For Multiplex Biomarker Kits 39
Acquisition 40
Myriad Genetics Acquires Counsyl for USD375 Million 40
Myriad Genetics Acquires Assurex Health for USD351.6 Million 42
Myriad Genetics Acquires Sividon Diagnostics 44
Myriad Genetics Completes Acquisition Of Crescendo Bioscience For US$270 Million 45
Myriad Genetics Inc – Key Competitors 47
Myriad Genetics Inc – Key Employees 48
Myriad Genetics Inc – Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 51
Financial Announcements 51
Aug 21, 2018: Myriad Genetics reports fiscal fourth-quarter and full-year 2018 financial results 51
May 08, 2018: Myriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results 54
Feb 06, 2018: Myriad Genetics Reports Fiscal Second-Quarter 2018 Financial Results 56
Nov 07, 2017: Myriad Genetics Reports Fiscal First-Quarter 2018 Financial Results 58
May 02, 2017: Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results 59
Feb 07, 2017: Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results 61
Legal and Regulatory 63
Apr 23, 2018: Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against  Myriad Genetics, Inc. 63
Government and Public Interest 64
Sep 25, 2018: Myriad Announces Publication of Variant Reclassification Study in the Journal of the American Medical Association 64
Product News 65
Apr 17, 2017: Study Finds Wide Gap in Quality of BRCA1/2 Variant Classification Between Myriad Genetics and A Common Public Database 65
Other Significant Developments 67
Oct 02, 2017: Myriad Genetics Highlights Strong Commitment to Preventing and Fighting Breast Cancer as Part of Breast Cancer Awareness Month 67
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68

List of Tables
Myriad Genetics Inc, Medical Equipment, Key Facts, 2018 2
Myriad Genetics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Myriad Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Myriad Genetics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Myriad Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Myriad Genetics Inc, Deals By Market, 2012 to YTD 2018 9
Myriad Genetics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Myriad Genetics to Raise Funds through Venture Financing 13
AssureRx Health Raises Additional USD15 Million in Series D Financing 14
AssureRx Health Raises USD7 Million in Venture Financing 15
Counsyl Raises US$28 Million In Series D Financing 17
RainDance Technologies Raises US$20 Million In Series E Financing 18
Crescendo Bioscience Raises US$28 Million In Series D Financing 20
Counsyl Secures USD7.5 Million in Series C Funding 22
Assurex Health Secures USD12.5 Million in Series C Funding Round 23
Counsyl Secures USD34 Million in Series B Round of Funding 24
Assurex Health Secures USD8 Million in Venture Funding Round 25
Perceptive Advisors Invests USD80 Million in Counsyl 26
Myriad Genetics Enters into Licensing Agreement with Institut Curie and INSERM 27
Myriad Genetics Enters into Licensing Agreement With Children’s Medical Center 28
Myriad Genetics Enters into Licensing Agreement with University of Texas 29
Myriad Genetics Enters Into Licensing Agreement For RAD51C Gene 30
Myriad Genetics and Pfizer Enter into Agreement 31
Sividon Diagnostics Enters into Co-Marketing Agreement with Virchow Labs and Ready Ruixin 32
Myriad Genetics Expands Agreement with AstraZeneca 33
Myriad Genetics Enters Into Co-Marketing Agreement With Sividon Diagnostics For EndoPredict Test 34
Myriad Enters Into Research Agreement With Janssen Research & Development 35
Myriad Genetics Expands Agreement with AstraZeneca for Olaparib 36
DaVita Enters Into Agreement With Myriad Genetics For Protein Biomarker Discovery 37
Mount Sinai Genetic Testing Lab And Counsyl Partner To Expand Screening For Genetic Diseases 38
Bio-Rad Labs Enters Into Distribution Agreement With Myriad RBM For Multiplex Biomarker Kits 39
Myriad Genetics Acquires Counsyl for USD375 Million 40
Myriad Genetics Acquires Assurex Health for USD351.6 Million 42
Myriad Genetics Acquires Sividon Diagnostics 44
Myriad Genetics Completes Acquisition Of Crescendo Bioscience For US$270 Million 45
Myriad Genetics Inc, Key Competitors 47
Myriad Genetics Inc, Key Employees 48
Myriad Genetics Inc, Subsidiaries 49

List of Figures
Myriad Genetics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Myriad Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Myriad Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Myriad Genetics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Myriad Genetics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Myriad Genetics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Myriad Genetics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Myriad Genetics Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Myriad Genetics Inc (MYGN):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Invuity Inc (IVTY):企業の財務・戦略的SWOT分析
    Summary Invuity Inc (Invuity) is a medical technology company that develops and markets advanced surgical devices for the minimally invasive and minimal access procedures. The company offers illuminated surgical retractors, single-use handheld aspiration and universal drop-in intracavity illuminator …
  • Handelsbanken Great Britain:企業の戦略・SWOT・財務分析
    Handelsbanken Great Britain - Strategy, SWOT and Corporate Finance Report Summary Handelsbanken Great Britain - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Endress+Hauser AG:企業の戦略的SWOT分析
    Endress+Hauser AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Dhofar Tourism Company SAOG:企業の戦略・SWOT・財務情報
    Dhofar Tourism Company SAOG - Strategy, SWOT and Corporate Finance Report Summary Dhofar Tourism Company SAOG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • AyoxxA Biosystems GmbH:医療機器:M&Aディール及び事業提携情報
    Summary AyoxxA Biosystems GmbH (AyoxxA) is a life science tools company that provides protein analysis solutions. The company offers multiple detection kits, cytokine detection kits, human inflammation kits, mouse inflammation kits, and human opthalmology kits. Its services include complete testing …
  • E-CO Energi Holding AS:企業の戦略的SWOT分析
    E-CO Energi Holding AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Takara Bio Inc (4974):企業の財務・戦略的SWOT分析
    Summary Takara Bio Inc (Takara), a subsidiary of Takara Holdings Inc, is a biotechnology company that develops, manufactures and distributes biotechnology research reagents and equipments for life sciences research. The company sells gene amplification system and offers scientific instruments. It of …
  • Transgene Biotek Ltd (526139):製薬・医療:M&Aディール及び事業提携情報
    Summary Transgene Biotek Ltd (Transgene) is a biotechnology company that develops and commercializes biogeneric drugs, vaccines and biotech products. The company develops products in the areas of oncology, auto-immunity, drug delivery and bio generics. Its products include TBL-0404, TBL-0905, TBL -0 …
  • Royal Dutch Shell Plc (RDSA)-石油・ガス分野:企業M&A・提携分析
    Summary Royal Dutch Shell plc (Shell) is an integrated oil and gas company. The company explores for and produces oil and gas from conventional fields and sources such as tight rock, shale and coal formations. Its refining and petrochemical complexes across the world add value to its upstream produc …
  • EyePoint Pharmaceuticals Inc (PSDV):企業の製品パイプライン分析2018
    Summary EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert and durasert, among others. Its durasert …
  • Ig Group Holdings Plc
    Ig Group Holdings Plc - Strategy, SWOT and Corporate Finance Report Summary Ig Group Holdings Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Sujana Universal Industries Ltd. (SUJANAUNI):企業の財務・戦略的SWOT分析
    Sujana Universal Industries Ltd. (SUJANAUNI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Anaconda Mining Inc:企業の戦略・SWOT・財務情報
    Anaconda Mining Inc - Strategy, SWOT and Corporate Finance Report Summary Anaconda Mining Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Greer Laboratories Inc-製薬・医療分野:企業M&A・提携分析
    Summary Greer Laboratories Inc (Greer), a subsidiary of Stallergenes Greer plc, is a pharmaceutical company that provides allergy immunotherapy products and services to the healthcare industry. The company provides products in the area of human allergy, veterinary allergy and source materials. It of …
  • Landis+Gyr AG (LAND):電力:M&Aディール及び事業提携情報
    Summary Landis+Gyr AG (Landis+Gyr) is an integrated energy management company that provide end-to-end advanced metering solutions. It delivers comprehensive services including cloud services, managed services, smart grid services, software services, solutions consulting and support services. The com …
  • The New York Times Company (NYT):企業の財務・戦略的SWOT分析
    The New York Times Company (NYT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Kenzo Parfums NA, LLC:企業の戦略・SWOT・財務情報
    Kenzo Parfums NA, LLC - Strategy, SWOT and Corporate Finance Report Summary Kenzo Parfums NA, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Calavo Growers, Inc. (CVGW):企業の財務・戦略的SWOT分析
    Calavo Growers, Inc. (CVGW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • University of Chicago-製薬・医療分野:企業M&A・提携分析
    Summary University of Chicago (UOC) is an academic and research university that offers education and research in various disciplines. The university offers undergraduate, master’s and PhD programs in the areas of anthropology, art history, astronomy and astrophysics, biochemistry and molecular biolo …
  • Qorvo Inc (QRVO):企業の財務・戦略的SWOT分析
    Qorvo Inc (QRVO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆